Abstracts tagged "Methotrexate (MTX) and tofacitinib"

Abstract Number: 885 • 2018 ACR/ARHP Annual Meeting
Herpes Zoster in Tofacitinib Users with and without Concomitant Methotrexate and Glucocorticoids
Jeffrey R. Curtis¹, Fenglong Xie¹, Sasha Bernatsky², Shuo Yang¹, Lang Chen¹, Huifeng Yun¹ and Kevin Winthrop³, ¹University of Alabama at Birmingham, Birmingham, AL, ²Division of Rheumatology, The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³Oregon Health and Science University, Portland, OR
Background/Purpose: An increased incidence of herpes zoster (HZ) has been observed with Janus kinase inhibitors such as tofacitinib (TOF). However, among TOF users, a potentially…
Abstract Number: 1646 • 2016 ACR/ARHP Annual Meeting
Discontinuation of Methotrexate or Glucocorticoids in Patients with Rheumatoid Arthritis Treated with Tofacitinib: Clinical Efficacy Data from Long-Term Extension Studies
Roy Fleischmann¹, Jürgen Wollenhaupt², Stanley Cohen¹, Michael Weinblatt³, Lisy Wang⁴, Haiyun Fan⁵, John Andrews⁶, Liza Takiya⁵ and Eustratios Bananis⁵, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, ³Brigham and Women’s Hospital, Boston, MA, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, Collegeville, PA, ⁶Pfizer Inc, New York, NY
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. In a post-hoc analysis of the tofacitinib RA long-term extension (LTE) studies,…
Abstract Number: 2606 • 2016 ACR/ARHP Annual Meeting
Effect of Glucocorticoids on Clinical and Radiographic Efficacy Outcomes in Methotrexate-Naive Patients with RA Receiving Tofacitinib or Methotrexate Monotherapy: Analysis of Data from a Phase 3 Trial
Christina Charles-Schoeman¹, Désirée van der Heijde², Gerd Burmester³, Peter Nash⁴, Cristiano A.F Zerbini⁵, Carol A Connell⁶, Haiyun Fan⁷, Kenneth Kwok⁸, Eustratios Bananis⁷ and Roy Fleischmann⁹, ¹University of California, Los Angeles, Los Angeles, CA, ²Leiden University Medical Center, Leiden, Netherlands, ³Department of Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany, ⁴Nambour Hospital, Sunshine Coast and Department of Medicine, University of Queensland, Queensland, Australia, ⁵Centro Paulista de Investigação Clinica, São Paulo, Brazil, ⁶Pfizer Inc, Groton, CT, ⁷Pfizer Inc, Collegeville, PA, ⁸Pfizer Inc, New York, NY, ⁹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Patients (pts) with RA often receive concomitant treatment with glucocorticoids (GCs) to…
Abstract Number: 1633 • 2015 ACR/ARHP Annual Meeting
Long-Term Radiographic and Patient-Reported Outcomes Based on Clinical Disease Activity Index Responses with Tofacitinib at 6 Months
Vibeke Strand¹, Arthur Kavanaugh², Alan J. Kivitz³, Désirée van der Heijde⁴, Elaine Hoffmann⁵, Ermeg Akylbekova⁶, Arif Soonasra⁷, Mark Snyder⁷, Koshika Soma⁵, Eustratios Bananis⁷ and Josef S. Smolen⁸, ¹Biopharmaceutical Consultant, Portola Valley, CA, ²University of California, San Diego School of Medicine, LaJolla, CA, ³Altoona Center for Clinical Research, Duncansville, PA, ⁴Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁵Pfizer Inc, Groton, CT, ⁶Quintiles, Atlanta, GA, ⁷Pfizer Inc, Collegeville, PA, ⁸Medical University of Vienna, Vienna, Austria
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. This analysis assessed if patients achieving Clinical Disease Activity Index (CDAI) remission…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].